Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company's lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. Show more

Location: 2533 South Coast Highway 101, Cardiff, CA, 92007, United States | Website: https://www.viracta.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

707.4K

52 Wk Range

$0.01 - $0.58

Previous Close

$0.02

Open

$0.02

Volume

709,325

Day Range

$0.02 - $0.02

Enterprise Value

-3.514M

Cash

21.13M

Avg Qtr Burn

-8.699M

Insider Ownership

2.99%

Institutional Own.

21.22%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.